| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 16
| Issue : 8 | Page : 82-83 |
|
|
Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin
Pathum Sookaromdee1, Viroj Wiwanitkit2
1 TWS Medical Center, Bangkok, Thailand
2 Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India; Department of Medical Science, Faculty of Medicine, University of Nis, Nis, Serbia
Correspondence Address:
Pathum Sookaromdee
TWS Medical Center, Bangkok
Thailand
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jcrt.JCRT_368_18
|
|
|
Background: Cholangiocarcinoma is an important biliary tract cancer. The high incidence of this cancer is observed in tropical Asia. Several underlying factors are mentioned for this cancer including to diabetes mellitus. The use of the antidiabetic drug, metformin, is mentioned for possibility for decreasing risk for cholangiocarcinoma.
Methods: The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand.
Results: In this study, the authors estimated the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin.
Conclusion: The results show a slight decreased risk of cholangiocarcinoma in that scenario.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
